银屑病发病年龄与HLA-C*06:02对生物制剂生存的影响
基于英国BADBIR注册研究2007–2022年数据,纳入4250例分析发病年龄、3094例分析HLA-C*06:02状态,评估阿达木单抗、依那西普、司库奇尤单抗或乌司奴单抗的生存。结果显示发病年龄与生物制剂因无效或不良事件停药无显著差异,而HLA-C*06:02阳性者因无效停用乌司奴单抗的风险显著更低(aHR 0.56, 95% CI 0.42-0.75)。
要点
- 发病年龄(早发vs晚发)不影响生物制剂生存。
- HLA-C*06:02阳性与乌司奴单抗因无效停药风险降低相关。
- HLA-C*06:02可作为生物制剂生存的预测生物标志物。
核心结论
- HLA-C*06:02而非发病年龄是银屑病患者生物制剂生存的预测生物标志物。
研究设计与样本
- 基于BADBIR注册2007–2022年数据,纳入首次使用阿达木单抗、依那西普、司库奇尤单抗或乌司奴单抗且随访≥6个月的患者。
- 发病年龄分析队列4250例(早发2929例,晚发1321例);HLA-C*06:02分析队列3094例(阳性1603例,阴性1491例),后者来自BSTOP子集。
主要发现
- 早发与晚发银屑病患者在任何生物制剂因无效或不良事件停药方面均无显著差异。
- HLA-C*06:02阳性患者因无效停用乌司奴单抗的风险显著低于阴性患者(aHR 0.56, 95% CI 0.42-0.75)。
关键数值与推荐
- 早发银屑病定义为发病年龄≤40岁,晚发为>40岁;治疗启动时年龄≥50岁者纳入分类。
- 生物制剂生存定义为因无效或不良事件导致的治疗终止。
临床怎么用
- 临床选择生物制剂时,可考虑检测HLA-C*06:02以预测乌司奴单抗的生存。
- 发病年龄不作为生物制剂生存的预测因素。
局限性
- HLA-C*06:02分析仅基于BSTOP子集,可能存在选择偏倚。
- 观察性研究设计,无法完全排除混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have used real-world data to investigate the association between biologic therapy survival and age at psoriasis onset or HLA-C*06:02 status in patients with moderate-to-severe psoriasis. The robustness of these studies is limited by small sample size, short follow-up and diverse safety and effectiveness measures. OBJECTIVES: To describe biologic survival and explore whether the response to biologics is modified by age at psoriasis onset or HLA-C*06:02 status in patients with moderate-to-severe psoriasis. METHODS: Data from patients in the UK and the Republic of Ireland registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from 2007 to 2022 on a first course of adalimumab, etanercept, secukinumab or ustekinumab with at least 6 months' follow-up and a subset of BADBIR patients with available HLA-C*06:02 information registered to Biomarkers and Stratification To Optimise outcomes in Psoriasis (BSTOP) were analysed. Patients aged ≥ 50 years at treatment initiation were classified into early-onset psoriasis (EOP) (presenting in patients ≤ 40 years of age) and late-onset psoriasis (LOP) (presenting in patients > 40 years of age). BADBIR patients with available information in BSTOP were categorized as HLA-C*06:02- or HLA-C*06:02 + . Biologic survival was defined as treatment discontinuation associated with ineffectiveness or occurrence of adverse events (AEs). Adjusted survival function and hazard ratio (aHR) with 95% confidence interval (CI) were estimated using a flexible parametric model to compare discontinuing therapy between age at psoriasis onset and HLA-C*06:02 groups. Each model included exposure (biologics), effect modifier (age at onset or HLA-C*06:02 status), interaction terms and several baseline demographic, clinical and disease severity covariates. RESULTS: Final analytical cohorts included 4250 patients in the age at psoriasis onset group [2929 EOP (69%) vs. 1321 LOP (31%)] and 3094 patients in the HLA-C*06:02 status group [1603 HLA-C*06:02+ (52%) vs. 1491 HLA-C*06:02- (48%)]. There was no significant difference between EOP and LOP in drug survival associated with ineffectiveness or AEs for any biologics. However, compared with patients who were HLA-C*06:02-, patients who were HLA-C*06:02 + were less likely to discontinue ustekinumab for reasons associated with ineffectiveness (aHR 0.56, 95% CI 0.42-0.75). CONCLUSIONS: HLA-C*06:02, but not age at psoriasis onset, is a predictive biomarker for biologic survival in patients with psoriasis. Findings from this large cohort provide further, important information to aid clinicians using biologic therapies to manage patients with psoriasis.
引用
- Alabas OA, Mason KJ, Yiu ZZN, et al. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2024. PMID: 38051972. doi:10.1093/bjd/ljad481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。